Posted by Michael Wonder on 25 Sep 2023
Theratechnologies submits tesamorelin F8 formulation sBLA for FDA review
25 September 2023 - Theratechnologies today announced that the Company has filed a supplemental biologics license application for the F8 formulation of tesamorelin to the US FDA for review.
Tesamorelin is the only medication approved in the US for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy.
